IL12RB2抗体;IL12RB2 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gasrtic cancer tissue using P11844(IL12RB2 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P11844(IL12RB2 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The IL12RB2 antibody targets the interleukin-12 receptor beta 2 (IL12RB2), a key subunit of the IL-12 receptor complex. IL-12 is a pro-inflammatory cytokine critical in bridging innate and adaptive immunity, primarily by promoting Th1 cell differentiation and IFN-γ production. The IL-12 receptor consists of two subunits: IL12RB1 (common to both IL-12 and IL-23 receptors) and IL12RB2. which is specific to IL-12 signaling. IL12RB2 is expressed on activated T cells, NK cells, and dendritic cells, and its engagement with IL-12 triggers JAK-STAT signaling pathways, driving cellular immune responses against intracellular pathogens and tumors.

Antibodies against IL12RB2 are valuable tools for studying IL-12/IL-12R biology, including receptor expression patterns, signaling mechanisms, and functional roles in autoimmune diseases (e.g., psoriasis, multiple sclerosis), infectious diseases, and cancer immunotherapy. Dysregulation of IL-12 signaling, linked to IL12RB2 mutations or altered expression, has been implicated in immune disorders and susceptibility to infections. Researchers use IL12RB2-specific antibodies in techniques like flow cytometry, immunohistochemistry, and Western blot to investigate receptor localization, expression levels, and downstream signaling events. Additionally, therapeutic strategies targeting IL-12/IL12RB2 are being explored, making these antibodies relevant for preclinical and clinical studies aimed at modulating immune responses.